Related references
Note: Only part of the references are listed.Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
Estefania Garcia-Guerrero et al.
LEUKEMIA (2021)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis
Nico Gagelmann et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Sabarinath V. Radhakrishnan et al.
NATURE COMMUNICATIONS (2020)
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
Norris Lam et al.
NATURE COMMUNICATIONS (2020)
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah et al.
NATURE COMMUNICATIONS (2020)
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V. Hirayama et al.
BLOOD (2019)
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
Nicholas F. Kuhn et al.
CANCER CELL (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
Boris Gorovits et al.
BIODRUGS (2019)
CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Ruth Wester et al.
HAEMATOLOGICA (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
Eric L. Smith et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Managing the toxicities of CAR T-cell therapy
Sattva S. Neelapu
HEMATOLOGICAL ONCOLOGY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
Haiming Chen et al.
LEUKEMIA RESEARCH (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Thomas Nerreter et al.
NATURE COMMUNICATIONS (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Ashwini Balakrishnan et al.
CLINICAL CANCER RESEARCH (2019)
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Melissa Works et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
Caitlin L. Costello et al.
BLOOD (2019)
T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
Lekha Mikkilineni et al.
BLOOD (2019)
Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable
Stacey A. Cranert et al.
BLOOD (2019)
Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Rakesh Popat et al.
BLOOD (2019)
B Cell Maturation Antigen-Specific CAR T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
Nico Gagelmann et al.
BLOOD (2019)
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Jin Jie et al.
BLOOD (2019)
Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs™) As Compared to Peripheral Blood Lymphocytes (PBLs)
Eric R. Lutz et al.
BLOOD (2019)
Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure
Bei Bei Ding et al.
BLOOD (2019)
A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Hua Zhang et al.
BLOOD (2019)
CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma A 3.5-year follow-up case report
Chiyi Jiang et al.
MEDICINE (2019)
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan et al.
LANCET HAEMATOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri et al.
BLOOD (2019)
Long-Term Follow-up of a Phase 1, Firstin-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Bai-Yan Wang et al.
BLOOD (2019)
Identification and Validation of Predictive Biomarkers to CD19-and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Meng Wang et al.
BLOOD (2019)
A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
Chenggong Li et al.
BLOOD (2019)
Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+T Cell Central Memory Cell Subset
Enrique Zudaire et al.
BLOOD (2019)
Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Chunrui Li et al.
BLOOD (2019)
Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
Andrew J. Cowan et al.
BLOOD (2019)
Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
Carlos Fernandez de Larrea et al.
BLOOD (2019)
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Jesus G. Berdeja et al.
BLOOD (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma
Edward A. Stadtmauer et al.
BLOOD ADVANCES (2019)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (vol 3, e120505, 2018)
Alfred L. Garfall et al.
JCI INSIGHT (2019)
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Alfred L. Garfall et al.
BLOOD ADVANCES (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance
Sophia Danhof et al.
HAEMATOLOGICA (2018)
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
Maria-Luisa Schubert et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
A compound chimeric antigen receptor strategy for targeting multiple myeloma
K. H. Chen et al.
LEUKEMIA (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance
Sophia Danhof et al.
HAEMATOLOGICA (2018)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
Wenting Zheng et al.
LEUKEMIA (2018)
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
Eric L. Smith et al.
MOLECULAR THERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
David T. Teachey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
Esther Drent et al.
PLOS ONE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
De-Xiu Bu et al.
Oncotarget (2018)
Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
Monica Casucci et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
John K. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Adam Ajina et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta et al.
NATURE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Noelle Frey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Kerry S. Campbell et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study
Xiaolan Shi et al.
BLOOD (2018)
ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Cesar Sommer et al.
BLOOD (2018)
Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma
Damian J. Green et al.
BLOOD (2018)
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Tara Gregory et al.
BLOOD (2018)
T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies
Chunrui Li et al.
BLOOD (2018)
Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma
Yarong Liu et al.
BLOOD (2018)
A Protein-Based Method to Develop Allogeneic Chimeric Antigen Receptor T-Cells
Paul Maciocia et al.
BLOOD (2018)
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
Sham Mailankody et al.
BLOOD (2018)
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)
Sham Mailankody et al.
BLOOD (2018)
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
Luca Bernabei et al.
BLOOD (2018)
Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
Matteo Giovanni Carrabba et al.
BLOOD (2018)
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lydia Lee et al.
BLOOD (2018)
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma
Xiuli Wang et al.
CLINICAL CANCER RESEARCH (2018)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
R. Monjezi et al.
LEUKEMIA (2017)
Differentiation stage of myeloma plasma cells: biological and clinical significance
B. Paiva et al.
LEUKEMIA (2017)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
Jun Chen et al.
NATURE (2017)
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Naoki Hosen et al.
NATURE MEDICINE (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
Diogo Gomes-Silva et al.
CELL REPORTS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher A. Klebanoff et al.
JCI INSIGHT (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease
Sara Mastaglio et al.
BLOOD (2017)
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement
Chen Tian et al.
ANNALS OF HEMATOLOGY (2017)
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
Estefania Garcia-Guerrero et al.
BLOOD (2017)
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
D. Sommermeyer et al.
LEUKEMIA (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
Eric Sanchez et al.
CLINICAL CANCER RESEARCH (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
H. Suen et al.
LEUKEMIA (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy
Ivan Borrello et al.
FRONTIERS IN IMMUNOLOGY (2016)
Fine-tuning the CAR spacer improves T-cell potency
Norihiro Watanabe et al.
ONCOIMMUNOLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma
David L. Hermanson et al.
BLOOD (2016)
Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies
Laurent Poirot et al.
CANCER RESEARCH (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma
Andrew T. Hutchinson et al.
MOLECULAR IMMUNOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Overcoming nutrient limitations for cell-based production of influenza vaccine
Sara Yousef et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Robust isolation of malignant plasma cells in multiple myeloma
Ildiko Frigyesi et al.
BLOOD (2014)
Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
Vishnu C. Ramani et al.
MATRIX BIOLOGY (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
P. C. Schuberth et al.
GENE THERAPY (2013)
GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells
Yossi Cohen et al.
HEMATOLOGY (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma
Reuben Benjamin et al.
CANCER RESEARCH (2012)
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
Johanna Atamaniuk et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Yawara Kawano et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells
A. Barber et al.
GENE THERAPY (2011)
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease
Robert C. Rickert et al.
IMMUNOLOGICAL REVIEWS (2011)
Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells
Jose De Salort et al.
IMMUNOLOGY LETTERS (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen
S. Peinert et al.
GENE THERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
SLAM-Family Receptors: Immune Regulators with or without SAP-Family Adaptors
Andre Veillette
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
Jerome Moreaux et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
Elodie Belnoue et al.
BLOOD (2008)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Salima Hacein-Bey-Abina et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL
Micah J. Benson et al.
JOURNAL OF IMMUNOLOGY (2008)
Exploring the full spectrum of macrophage activation
David M. Mosser et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined Immunodeficient human multiple myeloma model
Paola Neri et al.
CLINICAL CANCER RESEARCH (2007)
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
Bernard M. Tijink et al.
CLINICAL CANCER RESEARCH (2006)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
J Moreaux et al.
BLOOD (2005)
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
F van Rhee et al.
BLOOD (2005)
The BAFF/APRIL system: life beyond B lymphocytes
LG Ng et al.
MOLECULAR IMMUNOLOGY (2005)
CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
PA Antony et al.
JOURNAL OF IMMUNOLOGY (2005)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
R Bellucci et al.
BLOOD (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers
F Mackay et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
A molecular compendium of genes expressed in multiple myeloma
JO Claudio et al.
BLOOD (2002)
Generation of polyclonal plasmablasts from peripheral blood B cells:: a normal counterpart of malignant plasmablasts
K Tarte et al.
BLOOD (2002)
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses
SL Xu et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
